<DOC>
	<DOCNO>NCT01132014</DOCNO>
	<brief_summary>This Five cohort sequential clinical trial subject recurrent ovarian , fallopian tube , primary peritoneal cancer determine feasibility safety well immunogenicity OC-DC , autologous vaccine comprise autologous dendritic cell ( DC ) load vitro lysate autologous oxidized tumor cell , administer intranodally alone , combination intravenous Bevacizumab cyclophosphamide combination intravenous Bevacizumab , cyclophosphamide aspirin . Study duration 24 month .</brief_summary>
	<brief_title>Autologous OC-DC Vaccine Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Subject recurrent ovarian ( include low malignant potential ) , fallopian tube , primary peritoneal cancer . Subject prior cytoreductive surgery yield tumor lysate preparation . Lysate must meet release criterion Subject 18 year age old . Subject ECOG performance status less equal 1 . Subject must understand sign study specific informed consent . Subject may receive chemotherapy therapy harvest tumor prior enrollment . Subjects achieve complete response follow chemotherapy still eligible participation Subject platinumsensitive ( progressionfree interval ≥ 6 month prior recent recurrence ) platinumresistant ( progressionfree interval &lt; 6 month prior recent recurrence ) . Subject recovered toxicity prior chemotherapy therapy ( grade 2 less ) . Subject may receive prior investigational therapy ( include immune therapy ) . Subject may receive prior hormonal therapy . Subject may receive prior radiation therapy ( except inguinal region ) must complete therapy prior enrollment . Subject least 4 week postoperative recovery surgery prior enrollment ensure complete wound healing . Subjects bowel resection surgery enroll cohort 2 begin protocol least 42 day surgery debulking surgery comprise bowel resection bowel surgery . Subjects screen fails reenrolled causation screen fail correct . EXCLUSION CRITERIA Subject tumor lysate meet release criterion Subject positive serum Yo antibody Subject whose groin accessible . Subject chronic acute hepatitis C infection . Subject old infection clear may include . Subject chronic acute hepatitis B infection . Subject old infection clear may include . Subject positive test result screen visit one following : 1 . HTLV1/2 2 . AntiHIV 1 Antibody ( αHIV1 ) Subject require likely require twoweek course corticosteroid intercurrent illness . Subject must complete course corticosteroid 2 week screen meet eligibility . Subject renal insufficiency define serum creatinine great 2.2 mg/dl BUN great 40 mg/dl . Note : If creatinine great 1.5 x ULN , creatinine clearance must great 60ml/min . Subject proteinuria great 3.5 gm 24 hr eligible study ( cohort 2 ) Subject liver failure define serum total bilirubin great 2.0 and/or serum transaminase great 3X upper limit normal . Subject hematopoietic failure baseline define one following : 1 . Platelets le 100,000/ mm3 2 . WBC less 2,500/mm3 3 . Absolute Neutrophil Count ( ANC ) less 1,000/mm3 4 . Absolute lymphocyte count le 200/ mm3 5 . Hematocrit le equal 30 percent Subject acute infection require specific therapy . Acute therapy must complete within seven day prior study enrollment . Subject serious , nonhealing wound , ulcer , bone fracture . Subject clinically significant cardiovascular disease include : Uncontrolled hypertension ; Myocardial infarction unstable angina within 6 month prior enrollment New York Heart Association ( NYHA ) Grade II great congestive heart failure Subject grade II great peripheral vascular disease . Subject clinically significant peripheral artery disease , e.g. , claudication , within 6 month . Subject underlying condition , would contraindicate therapy study treatment ( allergies reagent use study ) . Subject organ allograft . Subject receive medication ( ) might affect immune function . Use H2 antagonist prohibit antihistamine five day five day injection study vaccine . However , NSAIDS include COX2 inhibitor , acetaminophen aspirin permit . Subject clinical symptom sign partial complete gastrointestinal obstruction require parenteral hydration and/or nutrition ( For cohort 2 , 3 , 4 5 ) . Subjects History bowel obstruction , include subocclusive disease , relate underlying disease history abdominal fistula , gastrointestinal perforation intraabdominal abscess . Subjects evidence rectosigmoid involvement pelvic examination bowel involvement CT scan clinical symptom bowel obstruction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Subjects recurrent ovarian , fallopian tube primary peritoneal cancer ,</keyword>
	<keyword>solid tumor ascites harvest available</keyword>
	<keyword>sufficient tumorlysate preparation ; whose large tumor nodule 4.5</keyword>
	<keyword>cm . Subjects may undergo chemotherapy therapy follow</keyword>
	<keyword>tumor harvest prior enrollment .</keyword>
</DOC>